151 related articles for article (PubMed ID: 38695911)
1. [Benign mesothelial tumors].
Tischoff I; Theile A
Pathologie (Heidelb); 2024 May; ():. PubMed ID: 38695911
[TBL] [Abstract][Full Text] [Related]
2. The significance of BAP1 and MTAP/CDKN2A expression in well-differentiated papillary mesothelial tumour: a series of 21 cases and a review of the literature.
Hassan A; Prabhakaran S; Pulford E; Hocking AJ; Godbolt D; Ziad F; Pandita A; Wessels A; Hussey M; Russell PA; Klebe S
Pathology; 2024 May; ():. PubMed ID: 38789301
[TBL] [Abstract][Full Text] [Related]
3. Well differentiated papillary mesothelial tumor: a new name and new problems.
Churg A; Galateau-Salle F
Mod Pathol; 2022 Oct; 35(10):1327-1333. PubMed ID: 35440764
[TBL] [Abstract][Full Text] [Related]
4. Mesothelioma of Uncertain Malignant Potential (MUMP) of the Tunica Vaginalis: Proposal for Reclassification as "Complex Mesothelial Tumor of the Tunica Vaginalis".
Ding CC; Van Roo J; Kryvenko ON; Ye H; McKenney JK; Epstein JI
Am J Surg Pathol; 2024 Apr; 48(4):387-394. PubMed ID: 38270560
[TBL] [Abstract][Full Text] [Related]
5. New developments in mesothelial pathology.
Churg A
Histopathology; 2024 Jan; 84(1):136-152. PubMed ID: 37694811
[TBL] [Abstract][Full Text] [Related]
6. Localized and diffuse mesotheliomas of the genital tract and peritoneum in women. A clinicopathologic study of nineteen true mesothelial neoplasms, other than adenomatoid tumors, multicystic mesotheliomas, and localized fibrous tumors.
Goldblum J; Hart WR
Am J Surg Pathol; 1995 Oct; 19(10):1124-37. PubMed ID: 7573671
[TBL] [Abstract][Full Text] [Related]
7. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
Berg KB; Dacic S; Miller C; Cheung S; Churg A
Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
[TBL] [Abstract][Full Text] [Related]
8. Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42.
Stevers M; Rabban JT; Garg K; Van Ziffle J; Onodera C; Grenert JP; Yeh I; Bastian BC; Zaloudek C; Solomon DA
Mod Pathol; 2019 Jan; 32(1):88-99. PubMed ID: 30171198
[TBL] [Abstract][Full Text] [Related]
9. Mesotheliomas and Benign Mesothelial Tumors: Update on Pathologic and Imaging Findings.
Bonde A; Singh R; Prasad SR; Kamireddy D; Aggarwal A; Ramani N; Saboo S; Shanbhogue K; Dasyam AK; Katabathina VS
Radiographics; 2023 Mar; 43(3):e220128. PubMed ID: 36757881
[TBL] [Abstract][Full Text] [Related]
10. A diagnostic approach to paratesticular lesions with tubulopapillary architecture: a series of 16 serous borderline tumors/low-grade serous carcinoma and 14 well-differentiated papillary mesothelial tumors and mesothelioma.
Zafar R; Schrader LJ; Cheville JC; Schoolmeester JK; Roden AC; Aubry MC; Yi ES; Raghunathan A; Herrera-Hernandez L; Thompson RH; Boorjian SA; Leibovich BC; Keeney GL; Jimenez RE; Gupta S
Hum Pathol; 2022 Oct; 128():31-47. PubMed ID: 35809685
[TBL] [Abstract][Full Text] [Related]
11. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations.
Sheffield BS; Hwang HC; Lee AF; Thompson K; Rodriguez S; Tse CH; Gown AM; Churg A
Am J Surg Pathol; 2015 Jul; 39(7):977-82. PubMed ID: 25634745
[TBL] [Abstract][Full Text] [Related]
12. BAP1 Loss is a Useful Adjunct to Distinguish Malignant Mesothelioma Including the Adenomatoid-like Variant From Benign Adenomatoid Tumors.
Erber R; Warth A; Muley T; Hartmann A; Herpel E; Agaimy A
Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):67-73. PubMed ID: 30640754
[TBL] [Abstract][Full Text] [Related]
13. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.
Cigognetti M; Lonardi S; Fisogni S; Balzarini P; Pellegrini V; Tironi A; Bercich L; Bugatti M; Rossi G; Murer B; Barbareschi M; Giuliani S; Cavazza A; Marchetti G; Vermi W; Facchetti F
Mod Pathol; 2015 Aug; 28(8):1043-57. PubMed ID: 26022455
[TBL] [Abstract][Full Text] [Related]
14. TRAF7 mutations and immunohistochemical study of uterine adenomatoid tumor compared with malignant mesothelioma.
Itami H; Fujii T; Nakai T; Takeda M; Kishi Y; Taniguchi F; Terada C; Okada F; Nitta Y; Matsuoka M; Sasaki S; Sugimoto S; Uchiyama T; Morita K; Kasai T; Kawaguchi R; Ohbayashi C
Hum Pathol; 2021 May; 111():59-66. PubMed ID: 33667423
[TBL] [Abstract][Full Text] [Related]
15. Solid papillary mesothelial tumor.
Churg A; Le Stang N; Dacic S; Pissaloux D; Begueret H; Dartigues P; Giusiano-Courcambeck S; Sequeiros R; Pairon JC; Tirode F; Galateau-Sallé F
Mod Pathol; 2022 Jan; 35(1):69-76. PubMed ID: 34480081
[TBL] [Abstract][Full Text] [Related]
16. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.
Joseph NM; Chen YY; Nasr A; Yeh I; Talevich E; Onodera C; Bastian BC; Rabban JT; Garg K; Zaloudek C; Solomon DA
Mod Pathol; 2017 Feb; 30(2):246-254. PubMed ID: 27813512
[TBL] [Abstract][Full Text] [Related]
17. New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
Churg A; Sheffield BS; Galateau-Salle F
Arch Pathol Lab Med; 2016 Apr; 140(4):318-21. PubMed ID: 26288396
[TBL] [Abstract][Full Text] [Related]
18. Peritoneal papillary mesothelioma in situ: BAP1 mutation with indolent behavior for 15 years.
Vitlarov N; Burtscher E; Pfeiffenberger E; Wahl A; Hodja V; Jasarevic Z; Kashofer K; Offner FA
Virchows Arch; 2023 Dec; 483(6):873-878. PubMed ID: 37428268
[TBL] [Abstract][Full Text] [Related]
19. Malignant mesothelioma in situ: diagnostic and clinical considerations.
Pulford E; Henderson DW; Klebe S
Pathology; 2020 Oct; 52(6):635-642. PubMed ID: 32829890
[TBL] [Abstract][Full Text] [Related]
20. Pleural mesothelioma classification-update and challenges.
Dacic S
Mod Pathol; 2022 Jan; 35(Suppl 1):51-56. PubMed ID: 34465883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
